As India and the United Kingdom edge closer to finalizing their much-anticipated Free Trade Agreement (FTA), a growing chorus of voices is sounding the alarm over what this deal could mean for public health in India. While the FTA promises economic growth, smoother trade channels, and better market access, experts warn that its implications for access to affordable medicines and healthcare protections could be deeply concerning.
The Price of Trade: Could Public Health Be the Hidden Cost?
Free trade agreements are typically designed to open markets and streamline regulations. But when it comes to sectors like healthcare, such agreements can carry unintended consequences. According to health advocates and civil society groups, some of the provisions in the India-UK FTA—particularly those around intellectual property rights (IPR) and pharmaceutical patents—may end up undermining India’s ability to produce affordable generic medicines.
India is known as the “pharmacy of the Global South” for a reason—it produces low-cost, high-quality generic drugs that are exported around the world, especially to developing nations. However, if the FTA enforces stricter patent regimes or data exclusivity clauses, it could delay the entry of generics into the market, keeping life-saving drugs out of reach for millions.
Stricter Patents, Higher Prices?
One of the most controversial elements reportedly under negotiation is the extension of pharmaceutical patent periods. This could potentially allow multinational drug companies—many based in the UK—to extend their monopolies on essential medicines far beyond their original terms. If such provisions make it into the final agreement, the price of critical medicines in India could skyrocket, making treatment for conditions like HIV, cancer, diabetes, and tuberculosis unaffordable for large segments of the population.
The impact wouldn’t just be limited to India. Countries across Africa and Southeast Asia that rely on Indian generics for public health programs could also find themselves squeezed by price hikes and delayed access.
Threat to Generic Medicine Production
India’s generic drug industry has thrived because of its flexible patent laws and a focus on public interest. However, under pressure from high-income countries and international pharma lobbies, the India-UK FTA may push for TRIPS-plus provisions—measures that go beyond what is required by the WTO’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement.
Such measures can include patent term extensions, data exclusivity, and limiting compulsory licensing—a vital tool that allows governments to authorize the production of generics in emergencies. Experts argue that these demands favor corporate profits over human lives, and they risk dismantling the legal framework that has long protected access to affordable treatment in India.
Public Health Experts Sound the Alarm
Health rights organizations, doctors’ associations, and NGOs have all voiced concern about the lack of transparency in the negotiation process. The public and key stakeholders have been kept in the dark about the exact terms being discussed, leading to a growing distrust in the FTA’s intent.
Many experts are urging the Indian government to prioritize health safeguards during trade talks and resist pressure from powerful pharmaceutical interests. They argue that India must not allow the FTA to compromise its ability to serve its own people and those beyond its borders who rely on its life-saving medicines.
Striking a Balance: Trade Growth vs. Human Health
There’s no denying that a well-crafted FTA with the UK could bring economic benefits, especially in sectors like textiles, services, and information technology. But these gains must not come at the expense of public health. A truly balanced trade agreement should protect the interests of both businesses and the broader population—particularly in a country where millions still struggle with access to affordable healthcare.
Governments on both sides need to recognize that economic prosperity is meaningless without a healthy population. Strengthening the health sector through collaboration—rather than restricting it through over-regulation—should be the real goal of any forward-looking trade pact.
Conclusion: Public Health Must Not Be a Bargaining Chip
As the India-UK FTA nears the finish line, it is crucial for policymakers to tread carefully and consciously. The decisions made today will shape the healthcare landscape for decades to come. Trade should empower people, not limit their access to the very things that keep them alive.